HALOHALOZYME THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of HALOZYME THERAPEUTICS, INC. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HALOThis | $12.8B#2 | 33.0x#1 | 89.0x#12 | 9.1x#1 | 37.6%#4 | -28.6%#8 | 33.6%#1 | 220.8%#1 | 15.0%#1 | — | 46.7%#10 | — |
| MRNA | $61.5B#1 | — | 9.1x#7 | 31.6x#3 | -39.9%#7 | 20.8%#5 | -158.1%#4 | -41.7%#11 | -54.6%#4 | — | 504.1%#4 | — |
| TWST | $10.5B#3 | — | 23.5x#10 | 27.8x#2 | 20.3%#5 | 62.8%#1 | -36.2%#2 | -17.4%#7 | -41.4%#3 | — | 497.4%#5 | — |
| ORKA | $6.3B#10 | — | 5.6x#2 | — | — | -25.9%#7 | — | -9.5%#5 | — | — | 472.3%#6 | — |
| KYMR | $9.8B#4 | — | 6.5x#5 | 249.8x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 20.6%#2 | — | — | 130.3%#7 | — |
| VKTX | $3.4B#12 | — | 8.3x#6 | — | — | -227.1%#13 | — | -88.1%#12 | — | — | 11.3%#12 | — |
| PRAX | $8.4B#7 | — | 6.2x#3 | — | -100.0%#8 | -65.6%#11 | — | -22.6%#9 | — | — | 561.0%#3 | — |
| ERAS | $5.2B#11 | — | 14.3x#8 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | 688.8%#1 | — |
| RYTM | $6.7B#8 | — | 65.2x#11 | 35.4x#4 | 45.8%#3 | 24.6%#3 | -101.2%#3 | -0.2%#4 | -133.8%#5 | — | -1.1%#13 | — |
| CGON | $6.6B#9 | — | 6.4x#4 | 1639.6x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#2 | — | 92.5%#8 | — |
| SLS | $2.3B#13 | — | 16.9x#9 | — | -100.0%#8 | 13.0%#6 | — | -19.5%#8 | — | — | 616.5%#2 | — |
| PCVX | $8.7B#6 | — | 3.1x#1 | — | — | -65.2%#10 | — | -0.0%#3 | — | — | 78.5%#9 | — |
| CYTK | $9.6B#5 | — | — | 108.5x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | 39.3%#11 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-19.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice